Literature DB >> 22460148

How to define remission in ankylosing spondylitis?

Joachim Sieper1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22460148     DOI: 10.1136/annrheumdis-2011-200798

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  7 in total

1.  [Treat-to-target (T2T) recommendation for patients with spondyloarthritis - translation into German].

Authors:  U Kiltz; J Sieper; M Backhaus; B Buss; E Gromnica-Ihle; H Haíbel; L Hammel; K Karberg; S Rehart; M Rudwaleit; F Schuch; P Steffens-Korbanka; J Braun
Journal:  Z Rheumatol       Date:  2016-11       Impact factor: 1.372

Review 2.  Treat to Target in Axial Spondyloarthritis: Pros, Cons, and Future Directions.

Authors:  Jean W Liew; Maureen Dubreuil
Journal:  Rheum Dis Clin North Am       Date:  2020-05       Impact factor: 2.670

Review 3.  Treat to Target in Axial Spondyloarthritis: What Are the Issues?

Authors:  Abhijeet Danve; Atul Deodhar
Journal:  Curr Rheumatol Rep       Date:  2017-05       Impact factor: 4.592

4.  Imaging in rheumatology: reconciling radiology and rheumatology.

Authors:  Bernhard J Tins; Robin Butler
Journal:  Insights Imaging       Date:  2013-10-15

Review 5.  Improving the Management of Psoriatic Arthritis and Axial Spondyloarthritis: Roundtable Discussions with Healthcare Professionals and Patients.

Authors:  Marco Garrido-Cumbrera; Ottfrid Hillmann; Raj Mahapatra; David Trigos; Petra Zajc; Luisa Weiss; Galya Bostynets; Laure Gossec; Laura C Coates
Journal:  Rheumatol Ther       Date:  2017-06-09

Review 6.  Managing morbidity and treatment-related toxicity in patients with ankylosing spondylitis.

Authors:  Martin Bergman; Amy Lundholm
Journal:  Rheumatology (Oxford)       Date:  2018-03-01       Impact factor: 7.580

Review 7.  Defining the target: clinical aims in axial spondyloarthritis.

Authors:  Helena Marzo-Ortega; Katie M Gaffney; Karl Gaffney
Journal:  Rheumatology (Oxford)       Date:  2018-08-01       Impact factor: 7.580

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.